P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)

• Bruno Paiva,
• Anastasiia Zherniakova,
• Jorge Nuñez,
• Paula Rodríguez-Otero,
• Qian Shi,
• Nikhil Munshi,
• Brian Durie,
• Jesús San Miguel

Affiliations

Bruno Paiva

1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain

Anastasiia Zherniakova

1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain

Jorge Nuñez

1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain

Paula Rodríguez-Otero

1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain

Qian Shi

2 Mayo Clinic, Rochester, United States

Nikhil Munshi

3 Dana-Farber Cancer Institute, Boston, United States

Brian Durie

4 Cedars-Sinai Medical Center, Los Angeles, United States

Jesús San Miguel

1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain